Effect of coadministration of enriched Korean red ginseng (Panax ginseng) and American ginseng (Panax quinquefolius L) on cardiometabolic outcomes in type-2 diabetes: A randomized controlled trialopen access
- Authors
- Jovanovski, Elena; Smircic-Duvnjak, Lea; Komishon, Allison; Au-Yeung, Fei (Rodney); Sievenpiper, John L.; Zurbau, Andreea; Jenkins, Alexandra L.; Sung, Mi-Kyung; Josse, Robert; Li, Dandan; Vuksan, Vladimir
- Issue Date
- Sep-2021
- Publisher
- 고려인삼학회
- Keywords
- Ginseng; Hypertension; Randomized controlled trial; Type-2 diabetes
- Citation
- Journal of Ginseng Research, v.45, no.5, pp 546 - 554
- Pages
- 9
- Journal Title
- Journal of Ginseng Research
- Volume
- 45
- Number
- 5
- Start Page
- 546
- End Page
- 554
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/17533
- DOI
- 10.1016/j.jgr.2019.11.005
- ISSN
- 1226-8453
2093-4947
- Abstract
- Background
Diabetes mellitus and hypertension often occur together, amplifying cardiovascular disease (CVD) risk and emphasizing the need for a multitargeted treatment approach. American ginseng (AG) and Korean red ginseng (KRG) species could improve glycemic control via complementary mechanisms. Additionally, a KRG-inherent component, ginsenoside Rg3, may moderate blood pressure (BP). Our objective was to investigate the therapeutic potential of coadministration of Rg3-enriched Korean red Ginseng (Rg3-KRG) and AG, added to standard of care therapy, in the management of hypertension and cardiometabolic risk factors in type-2 diabetes.
Methods
Within a randomized controlled, parallel design of 80 participants with type-2 diabetes (HbA1c: 6.5–8%) and hypertension (systolic BP: 140–160 mmHg or treated), supplementation with either 2.25 g/day of combined Rg3-KRG + AG or wheat-bran control was assessed over a 12-wk intervention period. The primary endpoint was ambulatory 24-h systolic BP. Additional endpoints included further hemodynamic assessment, glycemic control, plasma lipids and safety monitoring.
Results
Combined ginseng intervention generated a mean ± SE decrease in primary endpoint of 24-h systolic BP (−3.98 ± 2.0 mmHg, p = 0.04). Additionally, there was a greater reduction in HbA1c (−0.35 ± 0.1% [–3.8 ± 1.1 mmol/mol], p = 0.02), and change in blood lipids: total cholesterol (−0.50 ± 0.2 mmol/l, p = 0.01), non-HDL-C (−0.54 ± 0.2 mmol/l, p = 0.01), triglycerides (−0.40 ± 0.2 mmol/l, p = 0.02) and LDL-C (−0.35 ± 0.2 mmol/l, p = 0.06) at 12 wks, relative to control. No adverse safety outcomes were observed.
Conclusion
Coadministration of Rg3-KRG + AG is an effective addon for improving BP along with attaining favorable cardiometabolic outcomes in individuals with type 2 diabetes. Ginseng derivatives may offer clinical utility when included in the polypharmacy and lifestyle treatment of diabetes.
Clinical trial registration
Clinicaltrials.gov identifier, NCT01578837;
Keywords
GinsengHypertensionRandomized controlled trialType-2 diabetes
- Files in This Item
-
Go to Link
- Appears in
Collections - 생활과학대학 > 식품영양학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.